New research will shed light on claims from commercial banks that cord blood–derived stem cells can be used in diseases beyond hematological disorders. Sarah Webb investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Laughlin, M.J. et al. N. Engl. J. Med. 344, 1815–1822 (2001).
Rocha, V. et al. Abstract 2342, presented at the 54th Annual Meeting and Exposition of the American Hematology Association, Atlanta. December 9, 2012.
Wagner, J.E. et al. Abstract 359, presented at the 54th Annual Meeting and Exposition of the American Hematology Association, Atlanta. December 10, 2012.
Fernandez, M.N. et al. Exp. Hematol. 31, 535–544 (2003).
de Lima, M. et al. N. Engl. J. Med. 367, 2305–2315 (2012).
Delaney, C. et al. Nat. Med. 16, 232–236 (2010).
Allison, M. Nat. Biotechnol. 30, 304 (2012).
Nietfeld, J.J. et al. Biol. Blood Marrow Transplant. 14, 316–322 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Webb, S. Banking on cord blood stem cells. Nat Biotechnol 31, 585–588 (2013). https://doi.org/10.1038/nbt.2629
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2629
This article is cited by
-
The third way of umbilical cord blood banking
Nature Biotechnology (2014)
